CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Inclusion Criteria

• •Newly diagnosed with acute myelogenous leukemia (except acute promyelocytic leukemia) and has failed one or two prior standard induction attempts. Failure is defined as:
• •≥ 30% bone marrow blasts with at least 20% cellularity at mid-cycle bone marrow biopsy or residual AML on subsequent\~ day 28 bone marrow biopsy by morphology, flow, PCR or FISH
• •Patients enrolling after only 1 failed induction attempt must meet at least one of the following additional eligibility criteria of high risk: ≥ 60 years of age adverse cytogenetics or molecular characteristics
• •HLA-haploidentical related donor (aged 12 to 70 years)
• •≥ 18, but \< 75 years of age
• •Karnofsky performance status ≥ 60%
• •Adequate organ function within 14 days of study registration (30 days for pulmonary and cardiac) as defined in section 4.5
• •Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the NK cell infusion (excluding preparative regimen pre-meds)
• •No prior hematopoietic transplant
• •Not pregnant or lactating
• •Sexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth control